Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-747S Phase III Trial in Thrombotic Stroke
jRCT2080224080Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prasugrel in ischemic stroke, myocardial infarction (MI), coronary arteriosclerosis and 1 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Started Oct 2018; status: completed.
02
Drugs
prasugrel
03
Conditions
ischemic strokemyocardial infarction (MI)coronary arteriosclerosisIschaemic cerebral disease
Beyond the preview
Go deeper on jRCT2080224080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224080.